4564 OncoTherapy Science,Inc.オンコセラピー・サイエンスTSE Growth / Pharmaceuticals
0 posts
OncoTherapy Science,Inc. (4564) at a glance
Prices are from Yahoo! Finance and may be delayed. Always check the latest price before trading.
OncoTherapy Science,Inc. (4564) Stock Price HistoryNear an all-time low
OncoTherapy Science,Inc. closed at ¥14.0 on Nov 20, 2026, −22.2% over 1 month, −33.3% over 1 year.
If you had invested ¥100,000 1 month ago, it would be worth ¥77,778 today (−22.2%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −10.0%, while this stock moved −22.2%.
Last 10 Trading Days
| Date | Close | Change | % Change |
|---|---|---|---|
| Nov 20 (Fri) | ¥14.0 | −1 | −6.67% |
| Nov 19 (Thu) | ¥15.0 | +0 | +0.00% |
| Nov 16 (Mon) | ¥15.0 | −1 | −6.25% |
| Nov 13 (Fri) | ¥16.0 | −1 | −5.88% |
| Nov 12 (Thu) | ¥17.0 | +0 | +0.00% |
| Nov 10 (Tue) | ¥17.0 | +1 | +6.25% |
| Nov 9 (Mon) | ¥16.0 | +0 | +0.00% |
| Nov 6 (Fri) | ¥16.0 | −1 | −5.88% |
| Nov 5 (Thu) | ¥17.0 | +0 | +0.00% |
| Nov 2 (Mon) | ¥17.0 | −1 | −5.56% |
If you had invested ¥100,000 3 months ago, it would be worth ¥66,667 today (−33.3%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −14.8%, while this stock moved −33.3%.
Last 10 Trading Days
| Date | Close | Change | % Change |
|---|---|---|---|
| Nov 20 (Fri) | ¥14.0 | −1 | −6.67% |
| Nov 19 (Thu) | ¥15.0 | +0 | +0.00% |
| Nov 16 (Mon) | ¥15.0 | −1 | −6.25% |
| Nov 13 (Fri) | ¥16.0 | −1 | −5.88% |
| Nov 12 (Thu) | ¥17.0 | +0 | +0.00% |
| Nov 10 (Tue) | ¥17.0 | +1 | +6.25% |
| Nov 9 (Mon) | ¥16.0 | +0 | +0.00% |
| Nov 6 (Fri) | ¥16.0 | −1 | −5.88% |
| Nov 5 (Thu) | ¥17.0 | +0 | +0.00% |
| Nov 2 (Mon) | ¥17.0 | −1 | −5.56% |
If you had invested ¥100,000 6 months ago, it would be worth ¥70,000 today (−30.0%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −8.5%, while this stock moved −30.0%.
Monthly Closes
| Month | Month-End Close | Monthly % |
|---|---|---|
| Nov 2026 | ¥14.0 | −22.2% |
| Oct 2026 | ¥18.0 | −14.3% |
| Sep 2026 | ¥21.0 | −4.5% |
| Aug 2026 | ¥22.0 | +15.8% |
| Jul 2026 | ¥19.0 | +5.6% |
| Jun 2026 | ¥18.0 | −14.3% |
| May 2026 | ¥21.0 | −12.5% |
If you had invested ¥100,000 1 year ago, it would be worth ¥66,667 today (−33.3%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +13.3%, while this stock moved −33.3%.
Monthly Closes
| Month | Month-End Close | Monthly % |
|---|---|---|
| Nov 2026 | ¥14.0 | −22.2% |
| Oct 2026 | ¥18.0 | −14.3% |
| Sep 2026 | ¥21.0 | −4.5% |
| Aug 2026 | ¥22.0 | +15.8% |
| Jul 2026 | ¥19.0 | +5.6% |
| Jun 2026 | ¥18.0 | −14.3% |
| May 2026 | ¥21.0 | −12.5% |
| Apr 2026 | ¥24.0 | +14.3% |
| Mar 2026 | ¥21.0 | +0.0% |
| Feb 2026 | ¥21.0 | +5.0% |
| Jan 2026 | ¥20.0 | +0.0% |
| Dec 2025 | ¥20.0 | −9.1% |
| Nov 2025 | ¥22.0 | ― |
If you had invested ¥100,000 3 years ago, it would be worth ¥53,846 today (−46.2%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +67.8%, while this stock moved −46.2%.
Yearly Closes
| Year | Year-End Close | Yearly % |
|---|---|---|
| 2026 (YTD) | ¥14.0 | −30.0% |
| 2025 | ¥20.0 | ― |
If you had invested ¥100,000 5 years ago, it would be worth ¥18,182 today (−81.8%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +96.3%, while this stock moved −81.8%.
Yearly Closes
| Year | Year-End Close | Yearly % |
|---|---|---|
| 2026 (YTD) | ¥14.0 | −30.0% |
| 2025 | ¥20.0 | ― |
If you had invested ¥100,000 in Oct 2005, it would be worth ¥3,004 today (−97.0%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +250.3%, while this stock moved −97.0%.
Yearly Closes
| Year | Year-End Close | Yearly % |
|---|---|---|
| 2026 (YTD) | ¥14.0 | −30.0% |
| 2025 | ¥20.0 | −20.0% |
| 2024 | ¥25.0 | +8.7% |
| 2023 | ¥23.0 | −55.8% |
| 2022 | ¥52.0 | −27.8% |
| 2021 | ¥72.0 | −37.4% |
| 2020 | ¥115 | +35.3% |
| 2019 | ¥85.0 | −27.4% |
| 2018 | ¥117 | −48.9% |
| 2017 | ¥229 | −14.9% |
| 2016 | ¥269 | −12.1% |
| 2015 | ¥306 | −47.7% |
| 2014 | ¥585 | +130.3% |
| 2013 | ¥254 | −3.1% |
| 2012 | ¥262 | +11.6% |
| 2011 | ¥235 | −36.9% |
| 2010 | ¥372 | +38.3% |
| 2009 | ¥269 | +10.5% |
| 2008 | ¥244 | −6.3% |
| 2007 | ¥260 | +17.1% |
| 2006 | ¥222 | −49.5% |
| 2005 | ¥440 | ― |
Daily, weekly and monthly closes (Yahoo! Finance, split-adjusted, dividends excluded). "All" covers the range Yahoo provides (from Oct 2005). Please check the latest prices before trading.
OncoTherapy Science,Inc. (4564) financial indicators
PER, ROE and dividend yield are based on company forecasts, calculated from earnings reports and the closing price after each trading day.
Key features of OncoTherapy Science,Inc. (4564)
Business overview
Together with one consolidated subsidiary, the company's main businesses are drug research and development, large-scale analysis testing of cancer genes, and R&D of cancer immunotherapy. It is an R&D-focused venture founded in April 2001 to commercialize the research results of Professor 「中村祐輔」, former director of the Human Genome Center at the Institute of Medical Science, University of Tokyo. As decoding of the human genome advances, genome-based drug discovery, which finds new drug targets from information on genes and the proteins they produce and examines the efficacy and safety of treatments, is becoming a reality. The company believes that identifying and targeting disease-related genes makes it possible to develop drugs that remove the cause of disease rather than symptomatic treatments that only ease symptoms.
Summarized from the annual securities report (fiscal year ended March 2026) filed on EDINET.
Position within Pharmaceuticals (79 companies)
| PBR | 2.87x | Above the sector median of 1.86x (No. 56 from the lowest) |
|---|---|---|
| Market cap | ¥5.7 bn | No. 60 in the sector (largest first) |
Ranks among stocks in the same Tokyo Stock Exchange sector (33 sectors). PER and PBR of zero or below (losses, negative equity) are excluded and ranked from the lowest.
Price milestones
| 52-week high | ¥31 | 4/20 |
|---|---|---|
| 52-week low | ¥14 | 11/20 |
| Current position | 0.0% | Where the low is 0% and the high is 100% (close on 11/20: ¥14) |
| Year to date | -30.0% | No. 54 of 77 in the sector (best first) |
| 1 year | -33.3% |
Based on closing prices (adjusted for stock splits, excluding dividends).
Kabutaro's ranking history
| Top 50 gainers | 3 times | Latest: 10/30 (No. 41) |
|---|---|---|
| Top 50 losers | 5 times | Latest: 10/26 (No. 34) |
Gainers and losers have been recorded since 9/2026.
Calculated as of 2026/11/20 17:30 JST. Updated every business day in the evening.
Recent disclosures (TDnet, in Japanese)
- 11/20 17:00臨時株主総会招集のための基準日設定及び臨時株主総会招集ならびに資本金の額の減少に関するお知らせ
- 11/06 17:002027年3月期第2四半期(中間期)決算短信〔日本基準〕(連結)
Filings from the past 12 months (2).
Posts
This board is shared with the Japanese and Chinese versions. Feel free to write in English, Chinese or Japanese.
No posts yet. Be the first to write something.
Write on the OncoTherapy Science,Inc. board
More Japanese stocks in English
- Nxera Pharma Co.,Ltd.4565
- KYORIN Pharmaceutical Co.,Ltd.4569
- HUMAN MADE Inc.456A
- Immuno-Biological Laboratories Co.,Ltd.4570
- Nano Holdings,Inc.4571
- Carna Biosciences,Inc.4572
- TAIKO PHARMACEUTICAL CO.,LTD.4574
- CanBas Co.,Ltd.4575
- D.Western Therapeutics Institute, Inc.4576
- Daito Pharmaceutical Co.,Ltd.4577
- RaQualia Pharma Inc.4579
- Le Lien Co.,Ltd.457A